Biopharmaceutical firm Attralus has completed a $25 million Series A financing designed to further validate its AT-01 pan-amyloid radiotracer for PET/CT.

Physicians do not currently have a sound method of zeroing in on this concern, but Washington University researchers may have found an answer. 

Along with conventional equipment such as aprons, collars, shields and caps, reusable pads should be commonplace for these medical staffers, experts wrote recently.

The Society of Nuclear Medicine & Molecular Imaging recently released its updated guidance on the topic.

Radioisotope Life Sciences currently operates 31 pharmacies across 18 states.

Those who learned they had elevated amyloid levels did not suffer from more short-term anxiety, depression or suicical thoughts, experts reported in JAMA Neurology.

Researchers used a single SPECT/CT scan performed post-therapy to estimate how much radiation a patient’s tumor and at-risk organs will absorb.

The win comes shortly after the Swiss-based company shared positive early results for its radiotracer during the Alzheimer’s Association International Conference.

Normal scores on thinking and memory tests at the start of a 14-year-long study were associated with fewer problems later in life, regardless of amyloid brain plaques.

Blue Earth Diagnostics announced that it has administered its new radiohybrid imaging agent to patients taking part in a clinical trial for prostate cancer.

In addition to his dedication to early cancer detection, the renowned 57-year-old physician developed a number of FDG PET algorithms used for managing cancer patients.

Memorial Sloan Kettering Cancer Center researchers described their findings as a "potent" first step forward in using oncology-based approaches to combat the virus.